This interview was conducted with Christopher Stephens, managing partner of Orrick, Herrington & Sutcliffe’s Asia offices with supporting responses from Xiang Wang, lead partner of the…
In Conversation
What was the transition like from academia into entrepreneurship and what challenges did you face in beginning this company? I realized during this period in the…
As growth has stalled in Europe, the US and Japan, many multinational companies are looking at China as part of a hedging strategy and a key…
“ "There is an ageing population [in China] with an epidemiological profile that is increasingly aligned with that of the West. These are elements that favor global… ”
Could you please give a brief introduction to the ABO and its history? ABO was established in 2005. The CRO business emerged in 2000 in China,…
You have a very long history in the Chinese pharmaceutical industry, first in the joint venture company Xian-Janssen and then in the China National Pharmaceutical Group.…
You have been here in China for about a year. What were your assumptions about China before you arrived and were things more or less what…
Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational?…
First, let me briefly introduce myself. I used to work in Fuxin, a small city in the industrially advanced province of Liaoning which is equivalent to…
Please introduce to our readers the general situation and driving force behind the creation of the Beijing Pharma and Biotech Center and its core mandate? Established…
You have an MD and you’ve worked in industry, but then you decided to become and entrepreneur. What challenges did you face in transitioning to starting…
Finnegan is a leader and expert on the topic of intellectual property and it entered Asia in the late 1980s with an office in Tokyo yet…
